Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.
|Videos|May 29, 2020
A 68-Year-Old Woman With Stage IV Ovarian Cancer
Author(s)Ramez N. Eskander, MD
Ramez Eskander, MD, presents the case of a 68-year-old woman with stage IV ovarian cancer, and discusses the management approach for this patient and similar cases.
Advertisement
Case Overview:
Initial Presentation
- A 68-year-old postmenopausal woman presented with fatigue, urinary frequency, early satiety, abdominal bloating and distention
- PMH: HTN, medically treated with lisinopril
- SH: retired; grandmother of 3; never-smoker; social alcohol use
- PE: abdominal distention, bloating, and a positive fluid wave test; otherwise unremarkable
Clinical work-up
- Pelvic exam with transvaginal ultrasound showed a right ovarian mass
- Chest/abdomen/pelvis CT with contrast revealed a right adnexal 5.3-cm complex mass, a suspicious intraparenchymal liver lesion, retroperitoneal lymph node enlargement and concurrent pleural effusion
- Lymph node and adnexal mass biopsy confirmed high-grade, epithelial ovarian cancer; positive cytology of pleural effusion
- T1N1M1
- Germline molecular testing showed BRCA1/2 wild-type, HRD+
- CA-125, 438 U/mL
- ECOG: 1
Treatment
- Patient underwent TAH/BSO, lymph node dissection, with suboptimal debulking; residual disease 1.3 cm
- Paclitaxel/carboplatin/bevacizumab + maintenance bevacizumab
- After 3 cycles, patient underwent second debulking surgery, R0
- Continued on bevacizumab for 6 more cycles
- Achieved partial response, post treatment CA-125, 40 U/mL
- Achieved partial response, post treatment CA-125, 40 U/mL
Follow-up
- At 3 months
- CA-125, 18 U/mL
- Chest/abdomen/pelvis CT showed no gross pelvic masses or nodes
- Pelvic exam was unremarkable
Advertisement
Related to this article
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.
The RASolute 309 trial is investigating frontline daraxonrasib plus the RAS G12D inhibitor zoldonrasib vs chemotherapy in advanced pancreatic ductal adenocarcinoma.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5